| Japanese |
|---|
| Title | 99mTc Teboroxime SPECTによる心筋血流評価とそのクリアランス |
|---|
| Subtitle | 原著 |
|---|
| Authors | 中嶋憲一*, 滝淳一*, 分校久志*, 谷口充*, 秀毛範至*, 久慈一英*, 久田欣一*, 清水賢巳** |
|---|
| Authors(kana) | |
|---|
| Organization | *金沢大学医学部核医学科, **第二内科 |
|---|
| Journal | 核医学 |
|---|
| Volume | 29 |
|---|
| Number | 4 |
|---|
| Page | 485-493 |
|---|
| Year/Month | 1992/4 |
|---|
| Article | 原著 |
|---|
| Publisher | 日本核医学会 |
|---|
| Abstract | 「要旨」99mTc teboroximeは心筋に高い集積性を示し, 早いクリアランスを有する心筋血流用放射性医薬品として注目されている, そこで, 201Tlによる心筋血流SPECTと所見を比較し, また断層で心筋のクリアランスを測定した. Teboroximeのデータ収集は連続反復収集により静注後4分後より3分間の画像を用いて再構成した. 両者のSPECT所見から, 15症例45領域について正常, 虚血, 梗塞の判定をしたところ, 33領域(73%)で一致した. また, 冠動脈狭窄部では対照部と比較して, 有意のクリアランス遅延を認めた(paired T検定により安静時p=0.0087, 負荷時p=0.0385). クリアランスと初期カウントのそれぞれの中隔/側壁比の間には, 正の相関(r=0.743)を認めた. Teboroximeは新しい心筋血流用放射性医薬品として今後の臨床応用が期待できる. |
|---|
| Practice | 臨床医学：一般 |
|---|
| Keywords | 99mTc teboroxime, Coronary artery disease, Dynamic SPECT, Clearance. |
|---|
| English |
|---|
| Title | Myocardial Perfusion and Clearance of 99mTc Teboroxime Assessed by SPECT |
|---|
| Subtitle | Original Article |
|---|
| Authors | Kenichi NAKAJIMA*, Junichi TAKI*, Hisashi BUNKO*, Mitsuru TANIGUCHI*, Noriyuki SHUKE*, Ichiei KUJI*, Kinichi HISADA*, Masami SHIMIZU** |
|---|
| Authors(kana) | |
|---|
| Organization | *Department of Nuclear Medicine, **Second Department of Internal Medicine, Kanazawa University Hospital |
|---|
| Journal | The Japanese Journal of nuclear medicine |
|---|
| Volume | 29 |
|---|
| Number | 4 |
|---|
| Page | 485-493 |
|---|
| Year/Month | 1992/4 |
|---|
| Article | Original article |
|---|
| Publisher | THE JAPANESE SOCIETY OF NUCLEAR MEDICINE |
|---|
| Abstract | [Summary]99mTc teboroxime is a new myocardial imaging agent that has characteristics of high accumulation in the heart and rapid clearance. We performed tomographic teboroxime study and compared the findings with that of 201Tl. Myocardial teboroxime clearance was calculated by dynamic single photon emission computed tomography (SPECT) using continuous repetitive rotation acquisition method. Teboroxime SPECT image was reconstructed by the three-minute data started from 4 minutes after injection. In 45 myocardial regions (15 patients), complete agreement between 201Tl and 99mTc teboroxime was obtained in 33 regions (73%), when the findings were classified as normal, ischemia and infarction. Significant delay in clearance was seen in the region of coronary stenosis (>-75%) compared with that in the control region (P=0.0087 at rest, and p=0.0385 at peak exercise by paired T test). Septum-to-lateral ratios of the clearance and myocardial initial count showed positive correlation (r=0.743). Further clinical application of this radiopharmaceutical is expected as a new myocardial imaging agent. |
|---|
| Practice | Clinical medicine |
|---|
| Keywords | 99mTc teboroxime, Coronary artery disease, Dynamic SPECT, Clearance. |
|---|